Legal4 Oct 2026, 01:00 pm
Sun Pharma Advanced Research Wins ₹2751 Lakhs CENVAT Credit Case
AI Summary
Sun Pharma Advanced Research Company Ltd has received a favorable outcome in its ongoing litigation before the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai. The Tribunal upheld a prior order, confirming the company's entitlement to a refund of accumulated CENVAT credit, along with consequential interest, amounting to ₹2751 Lakhs (₹27.51 Crore). The Revenue's appeal has been dismissed, and the litigation is now decided in favor of the company. This development is a significant positive for the company's financial position.
Key Highlights
- CESTAT upholds prior order in favor of Sun Pharma Advanced Research.
- Company entitled to refund of ₹2751 Lakhs CENVAT credit.
- Consequential interest also confirmed by the Tribunal.
- Revenue's appeal dismissed; litigation decided in company's favor.
- Significant positive financial development for the company.
Price Impact
More from SPARC